Clinical trials: Acute Myocardial Infarction With ST Segment Elevation
- Condition Acute Myocardial Infarction With ST Segment Elevation
- Funder type Industry (pharma, biotech, devices)
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Acute ST Elevation Myocardial Infarction
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients.
- Trial name
- NCT02835534
- Testing
- rhTNK-tPA, alteplase
- Where
- China
- Volunteers
- 818 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Myocardial Infarction
Safety of TG100-115 for Heart Attack Treated With Angioplasty
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow.
- Trial name
- NCT00103350
- Testing
- TG100-115
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- TargeGen
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
ST Elevation Myocardial Infarction
MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction
Prospective, non-randomized, single arm, multicenter observational study. The objective is to evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of de novo stenotic lesions in coronary arteries in…
- Trial name
- e-MASTER (NCT02292823)
- Testing
- MGuard™ Prime Embolic Protection Stent System
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- InspireMD
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Austria Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667016
- Where
- 8 sites in Austria
- Volunteers
- 305 people
- Sponsor
- Biotronik Vertriebs-GmbH
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Primary Objective: To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: To demonstrate the superior…
- Trial name
- TAO (NCT01076764)
- Testing
- Otamixaban, UFH, Eptifibatide
- Where
- 607 sites in United States, Argentina and 53 more
- Volunteers
- 13,220 people
- Sponsor
- Sanofi
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
Coronary Disease
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
The primary focus of this study is to explore the safety of a range of doses of rNAPc2 in subjects who are managed in hospitals that most typically practice an early invasive strategy (catheterization during the index admission).
- Trial name
- NCT00116012
- Testing
- rNAPc2
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Large Reperfused ST-Elevation Myocardial Infarction
CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)
The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a stem cell mobilizing agent, on cardiac function and infarct size and on safety and tolerability, in patients with reperfused ST-Elevation…
- Trial name
- CATCH-AMI (NCT01905475)
- Testing
- POL6326
- Where
- 17 sites in Austria, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Polyphor Ltd.
Acute Myocardial Infarction
STEMI Cool Pilot Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A)
A Multicenter, Prospective, Randomized-Controlled Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention In Patients with Acute Myocardial Infarction.
- Trial name
- STEMI Cool (NCT03361995)
- Testing
- Cooling Procedure using the ZOLL Thermogard XP3 IVTM System, PCI
- Sponsor
- ZOLL Circulation, Inc., USA
Coronary Stenosis, Periodontal Diseases
Periodontal Disease, Inflammation and Acute Coronary Syndromes
Recent studies have shown that the systemic inflammation caused by periodontal disease (PD) can determine important changes in the coronary arteries, favoring atherosclerosis progression and development of acute coronary…
- Conditions
- Coronary Stenosis, Periodontal Diseases, Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction
- Trial name
- ATHERODENT (NCT03395041)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 149 people
- Sponsor
- Cardio Med Medical Center
ST-Segment Elevation Myocardial Infraction
IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction
Myocardial Infarctions (MI) are commonly known as heart attacks. An ST-Segment Elevation Myocardial Infarction (STEMI) is a more severe type of heart attack.
- Trial name
- NCT01007461
- Testing
- Sodium Sulfide (Na2S) for Injection
- Sponsor
- Mallinckrodt
Non-ST Elevation Myocardial Infarction (NSTEMI)
Prevention of Acute Kidney Injury in Patients With NSTEMI
A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography.
- Trial name
- AKI (NCT04912141)
- Where
- 4 sites in Switzerland
- Volunteers
- 29 people
- Sponsor
- Pharming Technologies B.V.
Myocardial Infarction
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
Study OPL-0301-201 is intended to generate efficacy and safety data of OPL-0301 in participants with post-myocardial infarction (MI) left ventricular dysfunction (LVD)
- Trial name
- RESTORE (NCT05327855)
- Testing
- OPL-0301 Dose 1, OPL-0301 Dose 2
- Sponsor
- Valo Health, Inc.